# SAM #36C26127N0063

VA award for Novartis PLUVICTO treatments for Palo Alto

**Buyer:** VA Network Contracting Office 21
**Posted:** October 01, 2026
**Identifier:** 36C26127N0063
**NAICS:** 325412, 325414

The Department of Veterans Affairs awarded a requirement for PLUVICTO treatments for Veterans served by the Palo Alto VA Health Care System.
- Government buyer: Department of Veterans Affairs, VISN 5, Health Service Area 52, Regional Procurement Office West, Network Contracting Office 21, on behalf of VA Palo Alto Health Care System.
- Award: $4,115,311.20.
- **OEM and product:** Novartis Pharmaceuticals Corporation’s PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), NDC 69488-0010-61.
- Quantity: 54 treatments, with an option for 36 additional treatments. The justification also references an estimated quantity of 120 doses; the documents do not reconcile these quantities.
- Intended use: targeted radiopharmaceutical therapy for adult Veterans with PSMA-positive metastatic castration-resistant prostate cancer. Each Veteran requires six treatment cycles administered every six weeks.
- Notable requirement: the justification identifies the VA National Acquisition Center contract and Novartis as the only listed source for the required NDC.

### Description

<p>Awardee:&nbsp;NOVARTIS PHARMACEUTICALS CORPORATION</p>

<p>Award Amount:&nbsp;$4,115,311.20</p>

<p>Period of Performance: 10/1/2026 - 09/30/2027</p>

<p>Limited Source Justification Attached</p>

[View original listing](https://sam.gov/opp/30d0a8fd40fd46f8b7053462b39af931/view)